MedTrace Logo

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

NCT01326104 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-04-27

Study results available
· View outcomes & findings →

Summary

Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children affected by a recurrent brain tumor.

Approximately 35 patients with first recurrence of medulloblastoma (reMB)/supratentorial primitive neuroectodermal tumors (PNETs) will be treated with tumor-specific immune cells and dendritic cell vaccines to see what impact they have on the tumor.

Conditions

Interventions

BIOLOGICAL

TTRNA-xALT

TTRNA-xALT 3 x 10\^7/kg by intravenous injection once.

BIOLOGICAL

TTRNA-DCs

TTRNA-DCs 1 x 10\^7 by intradermal injection every 2 weeks for 3 total doses.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of Florida

    lead OTHER

Principal Investigators

  • Duane Mitchell, MD, PhD · University of Florida

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-07
Primary Completion
2020-03-28
Completion
2025-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326104 on ClinicalTrials.gov